The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
 
Jia Luo
No Relationships to Disclose
 
Chaitanya Bandlamudi
No Relationships to Disclose
 
Biagio Ricciuti
No Relationships to Disclose
 
Natalie Vokes
No Relationships to Disclose
 
Adam Jacob Schoenfeld
No Relationships to Disclose
 
Jacklynn V. Egger
No Relationships to Disclose
 
Jennifer L. Sauter
Stock and Other Ownership Interests - Merck; Thermo Fisher Scientific
 
Andrew J. Plodkowski
No Relationships to Disclose
 
Isabel Ruth Preeshagul
Consulting or Advisory Role - AstraZeneca; Pfizer
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Pfizer; Regeneron
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Pfizer
Other Relationship - Memorial Sloan-Kettering Cancer Center
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Microsoft; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Illumina; InVitae; Janssen; Novartis; Roche; Syapse; Takeda; Tango Therapeutics; Third Rock Ventures
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Barry S. Taylor
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Genentech
 
Hira Rizvi
No Relationships to Disclose
 
Mark Donoghue
No Relationships to Disclose
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; ARIAD; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Gritstone Bio; Hengrui Therapeutics; Maverick Therapeutics; Merck; Nektar; Neon Therapeutics; Novartis; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)
 
Matthew David Hellmann
Stock and Other Ownership Interests - Immunai; Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Immunai; Merck; Mirati Therapeutics; Nektar; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb